Ikaros changes the face of NuRD remodeling.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia.Haematologica · 2015
   Trial
2. GFI1 tethers the NuRD complex to open and transcriptionally active chromatin in myeloid progenitors.Communications biology · 2021
   Article
3. Established and emergent roles for Ikaros transcription factors in lymphoid cell development and function.Immunological reviews · 2021
   Review
4. Genome-wide identification of genes regulating DNA methylation using genetic anchors for causal inference.Genome biology · 2020
   Article
5. Effect of Notch and PARP Pathways' Inhibition in Leukemic Cells.Cells · 2018
   Article
6. A novel, non-canonical splice variant of the Ikaros gene is aberrantly expressed in B-cell lymphoproliferative disorders.PloS one · 2013
   Article

Corrections and comments

• Comment on
  Harnessing of the nucleosome-remodeling-deacetylase complex controls lymphocyte development and prevents leukemogenesis.2011

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as